Citation Impact
Citing Papers
Cancer Cell Dependence on Unsaturated Fatty Acids Implicates Stearoyl-CoA Desaturase as a Target for Cancer Therapy
2011
ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation
2009 StandoutScience
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
2019
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
2016
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
2015
Histone deacetylases and cancer
2007
Lipid metabolism in cancer
2012
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
2012
A New Protein Conjugation System in Human
1998 StandoutNobel
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family
1993 Standout
The multifaceted roles of fatty acid synthesis in cancer
2016
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra
2015
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
2019
Subunits of Yeast RNA Polymerase II Transcription Factor TFIIH Encoded by the CCL1 Gene
1996 StandoutNobel
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
2016
Diagnostic and therapeutic management of cancer of an unknown primary
2003
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Trans-splicing in C. elegans generates the negative RNAi regulator ERI-6/7
2008 StandoutNatureNobel
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
2013
PU.1 and Interferon Consensus Sequence-binding Protein Regulate the Myeloid Expression of the Human Toll-like Receptor 4 Gene
2000 StandoutNobel
Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain
2020 StandoutNobel
Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells
1996
Bladder cancer
2016 Standout
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
Nopp 140 shuttles on tracks between nucleolus and cytoplasm
1992 StandoutNobel
Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells
1998 Standout
Low risk of solid tumors in persons with Down syndrome
2016
Emerging Biological Principles of Metastasis
2017 Standout
Cellular Fatty Acid Metabolism and Cancer
2013 Standout
EMT: 2016
2016 Standout
High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis
2014 StandoutNobel
Targeting metastasis
2016
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
2013
New Therapeutic Challenges in Advanced Bladder Cancer
2012
Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis
2012
Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype
2012
MicroRNA expression profiles classify human cancers
2005 StandoutNatureNobel
Clonal evolution of chemotherapy-resistant urothelial carcinoma
2016
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
2018
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
2012
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
2017
lin-35 and lin-53, Two Genes that Antagonize a C. elegans Ras Pathway, Encode Proteins Similar to Rb and Its Binding Protein RbAp48
1998 StandoutNobel
Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinoma
2009
A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans
2004 StandoutNatureNobel
Molecular biology and targeted therapies for urothelial carcinoma
2015
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
A review of tasquinimod in the treatment of advanced prostate cancer
2013
Down Syndrome
2020 Standout
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature
2015
Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless.
1994 StandoutNobel
Neurexin III alpha: extensive alternative splicing generates membrane-bound and soluble forms.
1993 StandoutNobel
Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial
2014
The Ets family of transcription factors
1993
The Caenorhabditis elegans gene lin-1 encodes an ETS-domain protein and defines a branch of the vulval induction pathway.
1995 StandoutNobel
An integral membrane protein of the pore membrane domain of the nuclear envelope contains a nucleoporin-like region
1993 StandoutNobel
Differential expression and regulation of multiple dynamins.
1994 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis.
1994 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Involvement of the transcription factor PU.1/Spi-1 in myeloid cell-restricted expression of an interferon-inducible gene encoding the human high-affinity Fc gamma receptor.
1994
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
2016
Human TKTL1 implies greater neurogenesis in frontal neocortex of modern humans than Neanderthals
2022 StandoutScienceNobel
Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
2010
A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme.
1997 StandoutNobel
An analysis of vertebrate mRNA sequences: intimations of translational control.
1991 Standout
Current Status of Src Inhibitors in Solid Tumor Malignancies
2011
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter.
1993
Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics
2017 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Emerging Targets in Photopharmacology
2016 StandoutNobel
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]
2010
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
2013 StandoutScience
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
2011
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
2011
Second-Line Systemic Therapy for Metastatic Urothelial Carcinoma of the Bladder
2013
Works of Stéphane Culine being referenced
Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice
2010
The human homologue of the putative proto-oncogene Spi-1: characterization and expression in tumors.
1990
Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe
2014
Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study
2009
miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice
2009
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
2013
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
2015
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
2011
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
2006
Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
2011
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum–gemcitabine regimen
2012
A Lower Risk of Dying from Urological Cancer in Down Syndrome: Clue for Cancer Protecting Genes on Chromosome 21
2009
Arades Trial: A First-in-Man, Open-Label, Phase I/II Safety, Pharmacokinetic, and Proof-of-Concept Study of ODM-201 in Patients (PTS) with Progressive Metastatic Castration-Resistant Prostate Cancer (MCRPC)
2012
5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site.
2001
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
2009
Peroxisome Proliferator-Activated Receptor γ Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer
2006
Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study
2004
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
2009
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
2018
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
2010
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
2012